Zayoryl-M1 Forte 1000mg Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 1mg and Metformin 1000mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, functions by stimulating pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, increasing peripheral glucose uptake, and enhancing insulin sensitivity. This dual mechanism addresses both insulin deficiency and insulin resistance, making Zayoryl-M1 Forte effective in achieving optimal blood glucose levels when diet and exercise alone are insufficient. The prolonged-release formulation ensures a steady plasma concentration, reducing the frequency of dosing and improving patient compliance. It is essential to monitor renal function prior to and during therapy due to the risk of lactic acidosis associated with Metformin. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, while hypoglycemia risk is primarily attributed to Glimepiride. Zayoryl-M1 Forte should be used cautiously in patients with hepatic impairment, cardiovascular disease, or those undergoing radiologic studies involving iodinated contrast agents. Regular monitoring of blood glucose, HbA1c, and renal parameters is recommended to optimize therapeutic outcomes and minimize adverse effects.